key papersKey paper
European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)
The expert panel guidance on acute promyelocytic leukaemia covers the emergency first hours, the choice between arsenic-based and chemotherapy-based regimens by risk, differentiation syndrome, and molecular monitoring.
Overview
Updated recommendations from a European LeukemiaNet expert panel on diagnosis, supportive care for coagulopathy, risk-adapted treatment with all-trans retinoic acid and arsenic trioxide or chemotherapy, management of differentiation syndrome, molecular monitoring and treatment of relapse.
GuidelineChanged practice
Authors
Sanz MA, Sanz MA, Fenaux P, et al.
Published
Blood, 2019
What it means
Starting retinoic acid on morphological suspicion, aggressive blood product support and arsenic-based induction for non-high-risk disease all follow from this document.
Caveats
- Oral arsenic and gemtuzumab-based regimens for high-risk disease have evolved since publication.